# A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension

> **NCT04936035** · PHASE2 · COMPLETED · sponsor: **Alnylam Pharmaceuticals** · enrollment: 394 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Placebo
- **DRUG:** ALN-AGT01

## Key facts

- **NCT ID:** NCT04936035
- **Lead sponsor:** Alnylam Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-07
- **Primary completion:** 2023-04-04
- **Final completion:** 2024-12-05
- **Target enrollment:** 394 (ACTUAL)
- **Last updated:** 2025-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04936035

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04936035, "A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04936035. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*